RADIESSE® has been used to treat patients in over 57 countries worldwide. Radiesse was FDA approved for subdermal implantation for the correction of moderate to severe wrinkles and folds in 2006, and since that time over 6 million syringes have been sold worldwide. Radiesse works to add volume and may instantly hide the signs of wrinkles and creases for a more refreshed look. Individual results may vary.
Versatility of Sizes to Treat a Wide Range of Patients
In the U.S., RADIESSE is available in two convenient size options:
RADIESSE® Moderate Fill 0.8cc Syringe – for correction of moderate wrinkles and folds
RADIESSE® Volume Advantage 1.5cc Syringe – for correction of severe wrinkles and folds
Less is More
In two separate clinical studies comparing RADIESSE to other leading injectable dermal fillers, overall, patients required less RADIESSE to achieve full correction.2,4
- 33% less RADIESSE was required for full correction, versus JUVÉDERM® Injectable Gel 2
- 30% less RADIESSE was required for full correction when compared to Perlane®Injectable Gel 2
- 30% less RADIESSE was required for full correction when compared to Restylane®Injectable Gel 4
Less RADIESSE may be required for full correction giving your practice and your patients more value with each syringe.
References:
2Moers-Carpi M, Vogt S, Santos BM, Planas J, Vallve SR, Howell DJ. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg.2007;33(suppl 2):S144-S151.
4Moers-Carpi MM, Tufet JO. Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for the correction of nasolabial folds: a 12-month, multicenter, prospective, randomized, controlled, split-face trial. Dermatol Surg. 2008;34(2):210-215.
https://www.radiesse.com/professionals/about-radiesse/value/